Hepatitis C vaccine - Innogenetics

Drug Profile

Hepatitis C vaccine - Innogenetics

Alternative Names: E1 vaccine - Innogenetics; HCV E1 vaccine - Innogenetics; INNO 101; InnoVac-C; INNOVAX-C

Latest Information Update: 11 Sep 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innogenetics
  • Class Hepatitis C vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 07 Sep 2007 Discontinued - Phase-II for Hepatitis C in Belgium (IM)
  • 07 Sep 2007 Discontinued - Phase-II for Hepatitis C in Europe (IM)
  • 12 Jul 2005 Data presented at the 40th Annual Meeting of the European Association for the Study of the Liver (EASL-2005) have been added to the adverse events and Viral infections immunogenicity and therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top